For decades, migraine prevention relied on nonspecific, off-label drugs, often lacking large-scale clinical trials to confirm their efficacy, safety, or tolerability.^1-3 This has resulted in high discontinuation rates.^2,3 However, the introduction of calcitonin gene-related peptide (CGRP) pathway-targeting therapies has revolutionized migraine management.³ At a recent symposium, Dr. Sait Ashina, Director of the BIDMC Comprehensive Headache Center and Assistant Professor at Harvard Medical School in the United States (US), discussed how beyond randomized controlled trials (RCTs), the 5-year real-world evidence (RWE) data further demonstrate the utility of CGRP pathway-targeting therapies in the evolution of migraine prevention.

Migraine exhibits a 2-3 fold higher prevalence in women compared to men.1 Among females, migraines are typically of longer duration, more debilitating, and more likely to recur post-initial treatment.1 Studies have found that triptans were ineffective in up to 40% of migraine attacks.1  Rimegepant,

Caption